Loading
Every dated change on the records linked to PD-L1-high non-small-cell lung cancer without a driver mutation, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Nivolumab plus ipilimumab improved overall survival over chemotherapy in PD-L1-positive advanced non-small-cell lung cancer; approved in the United States in May 2020.
Median overall survival 20.
A milestone in how this cancer is treated.
Pembrolizumab plus carboplatin and a taxane improved overall and progression-free survival over chemotherapy alone across PD-L1 levels; approved in October 2018.
A milestone in how this cancer is treated.
Median overall survival 10.
5-year OS 31.
A milestone in how this cancer is treated.